Skip to main content
Log in

Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist

  • SHORT COMMUNICATION
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

This study evaluated the impact of route of progesterone administration as luteal phase support on the outcome of assisted conception cycles.

Methods

Intramuscular progesterone in oil (IMP) at 100 mg daily was administered to 903 women following oocyte retrieval whereas vaginal progesterone gel (VMP) at 90 mg was administered twice daily to 1,110 women. Retrospective analysis was performed according to the type of GnRH analogue used. Implantation (IR), clinical pregnancy (CPR) and biochemical pregnancy rates (BPR) were main outcomes.

Results

In GnRH agonist cycles, neither IR, CPR or BPR differed according to the route of progesterone. However, in GnRH antagonist cycles, IR and CPR were significantly lower in VMP group compared to IMP group. BPR also was significantly higher in VMP group compared to IMP group.

Conclusion

Our results suggest that route of progesterone administration for luteal phase support can be an important prognostic factor according to the type of GnRH analogue used for controlled ovarian hyperstimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357–9. doi:10.1016/S0015-0282(98)00135-6.

    Article  PubMed  CAS  Google Scholar 

  2. Kolibianakis EM, Devroey P. The luteal phase after ovarian stimulation. Reprod Biomed Online. 2002;5(Suppl):26–35.

    PubMed  Google Scholar 

  3. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod. 2005;20:2373–5. doi:10.1093/humrep/dei086.

    Article  PubMed  CAS  Google Scholar 

  4. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Human Reproduction Update. 2007;13:581–90.

    Article  PubMed  CAS  Google Scholar 

  5. Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318–23. doi:10.1016/S0015-0282(01)02961-2.

    Article  PubMed  Google Scholar 

  6. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev. 2004;CD004830.

  7. Levine H. Luteal support in IVF using the novel vaginal progesterone gel Crinone 8%: results of an open-label trial in 1,184 women from 16 US centers. Fertil Steril. 2000;74:836–7. doi:10.1016/S0015-0282(00)01497-7.

    Article  PubMed  CAS  Google Scholar 

  8. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6. doi:10.1016/S0029-7844(99)00542-6.

    Article  PubMed  CAS  Google Scholar 

  9. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–90.

    PubMed  CAS  Google Scholar 

  10. Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9. doi:10.1016/S0015-0282(99)00362-3.

    Article  PubMed  CAS  Google Scholar 

  11. Damario MA, Goudas VT, Session DR, Hammitt DG, Dumesic DA. Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil Steril. 1999;72:830–6. doi:10.1016/S0015-0282(99)00364-7.

    Article  PubMed  CAS  Google Scholar 

  12. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky E. Randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril. 2001;76:1144–9. doi:10.1016/S0015-0282(01)02872-2.

    Article  PubMed  CAS  Google Scholar 

  13. Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online. 2003;6:287–95.

    Article  PubMed  CAS  Google Scholar 

  14. Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–8. doi:10.1093/humrep/15.6.1284.

    Article  PubMed  CAS  Google Scholar 

  15. Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A randomized prospective study comparing supplementation of the luteal phase and early pregnancy by natural progesterone administered by intramuscular or vaginal route]: Reviews of (French). Gynecol Obstet (Paris). 1992;87:507–16.

    CAS  Google Scholar 

  16. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility. 2008;89:485–7.

    Article  PubMed  CAS  Google Scholar 

  17. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287–99. doi:10.1093/humrep/17.9.2287.

    Article  PubMed  CAS  Google Scholar 

  18. Dal Prato L, Bianchi L, Cattoli M, Tarozzi N, Flamigni N, Borini A. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod Biomed Online. 2008;16:361–7.

    PubMed  CAS  Google Scholar 

  19. Ruan HC, Zhu XM, Luo Q, Liu AX, Qian YL, Zhou CY, Jin F, Huang HF, Sheng JZ. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod. 2006;21:2521–9. doi:10.1093/humrep/del215.

    Article  PubMed  CAS  Google Scholar 

  20. Kumbak B, Ulug U, Erzik B, Akbas H, Bahceci M. Early clinical pregnancy loss rate in poor responder patients does not change compared to age-matched normoresponders. Fertil Steril. 2008.

  21. Bahceci M, Ulug U. Does underlying infertility aetiology impact on first trimester miscarriage rate following ICSI? A preliminary report from 1,244 singleton gestations. Hum Reprod. 2005;20:717–21. doi:10.1093/humrep/deh681.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mustafa Bahceci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bahceci, M., Ulug, U. Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist. J Assist Reprod Genet 25, 499–502 (2008). https://doi.org/10.1007/s10815-008-9269-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-008-9269-3

Keywords

Navigation